Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in rituximab-refractory iNHL (CHRONOS-2)
NCT02369016Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2015
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Indolent Non-Hodgkin Lymphoma (INHL) comparing Copanlisib with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 7 years, Number of Participants With Treatment-emergent Serious Adverse Events up to 7 years and 2 more. Started Sep 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT02369016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369016.